Cardiovascular Systems Inc | Business Contracts

Agreement and Plan of Merger, dated as of February 8, 2023, by and among the Company, Abbott Laboratories, and Cobra Acquisition Co (Filed With SEC on February 9, 2023)

Product Development Agreement, dated as of January 2 (Filed With SEC on February 9, 2023)

First Amended and Restated Acquisition Option Agreement, dated as of December 30, 2022, by and among the Company, Chansu Vascular Technologies, LLC, and the members of Chansu... (Filed With SEC on February 9, 2023)

Loan Agreement, dated as of December 30, 2022, by and between the Company and Chansu Vascular Technologies, LLC (Filed With SEC on February 9, 2023)

Separation Agreement, dated June 30, 2022, by and between the Company and David Whitescarver (Filed With SEC on August 18, 2022)

Fourth Amendment to Build-to-Suit Lease, between Pearland Economic Development Corporation and Cardiovascular Systems, Inc. dated December 18, 2020 (Filed With SEC on February 4, 2021)

Fiscal 2023 Executive Officer Bonus Plan and Equity Compensation (Filed With SEC on August 18, 2022)

Fiscal 2023 Director Compensation Arrangements (Filed With SEC on August 18, 2022)

Separation Agreement, dated June 6, 2022, by and between the Company and Rhonda Robb (Filed With SEC on August 18, 2022)

Consulting Agreement, dated July 1, 2022, by and between the Company and David Whitescarver (Filed With SEC on August 18, 2022)

Form of Performance-Vest Restricted Stock Award Agreement (Revenue Growth) under Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on August 18, 2022)

Form of Performance-Vest Restricted Stock Award Agreement (Total Stockholder Return) under Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on August 18, 2022)

Transition Agreement, dated December 16, 2021, by and between the Company and David Whitescarver (Filed With SEC on February 3, 2022)

Fiscal 2022 Director Compensation Arrangements (Filed With SEC on August 19, 2021)

Fiscal 2022 Executive Officer Bonus Plan and Equity Compensation (Filed With SEC on August 19, 2021)

Supply Agreement, between Cardiovascular Systems, Inc. and Fresenius Kabi AB, effective April 4, 2011 (Filed With SEC on November 5, 2020)

Amendment to Purchasing Agreement, effective October 1, 2020, between Cardiovascular Systems, Inc. and Healthtrust Purchasing Group, L.P (Filed With SEC on November 5, 2020)

Amendment No. 1 to Product Schedule, between Cardiovascular Systems, Inc. and Fresenius Kabi AB, effective March 27, 2016 (Filed With SEC on November 5, 2020)

Supply Agreement, between Cardiovascular Systems, Inc. and Abrasive Technology, Inc, effective June 19, 2020 (Filed With SEC on August 20, 2020)

Fiscal 2021 Executive Officer Bonus Plan and Equity Compensation (Filed With SEC on August 20, 2020)

Fiscal 2021 Director Compensation Arrangements (Filed With SEC on August 20, 2020)

Underwriting Agreement, dated June 9, 2020 (Filed With SEC on June 12, 2020)

Form of Performance-Vest Restricted Stock Award Agreement under Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on May 7, 2020)

Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on May 7, 2020)

Amendment No. 2 to Supply Agreement, between Cardiovascular Systems, Inc. and Fresenius Kabi AB, effective March 18, 2020 (Filed With SEC on May 7, 2020)

First Amendment to Loan and Security Agreement, by and between Cardiovascular Systems, Inc. and Silicon Valley Bank, dated March 26, 2020 (Filed With SEC on May 7, 2020)

Form of Stock Option Agreement under Amended and Restated 2017 Equity Incentive Form (Filed With SEC on May 7, 2020)

Form of Time-Vest Restricted Stock Award Agreement under Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on May 7, 2020)

Form of Board RSU Agreement (in lieu of cash retainer) under Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on May 7, 2020)

Form of Board RSU Agreement (annual) under Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on May 7, 2020)

Form of Board Restricted Stock Award Agreement (in lieu of cash retainer) under Amended and Restated 2017 Equity Incentive Plan (Filed With SEC on May 7, 2020)

Amendment No. 2 to Product Schedule, between Cardiovascular Systems, Inc. and Fresenius Kabi AB, effective March 18, 2020 (Filed With SEC on May 7, 2020)

Consulting Agreement dated August 31, 2019, by and between the Company and Laura J. Gillund (Filed With SEC on October 31, 2019)

Separation Agreement, dated August 30, 2019, by and between the Company and Laura J. Gillund (Filed With SEC on October 31, 2019)

Fiscal 2020 Executive Officer Bonus Plan and Equity Compensation (Filed With SEC on August 23, 2019)

Description of Capital Stock (Filed With SEC on August 23, 2019)

Fiscal Year 2020 Director Compensation Arrangements (Filed With SEC on August 23, 2019)

Transition Agreement, dated January 9, 2019, by and between the Company and Laura J. Gillund (Filed With SEC on May 3, 2019)

Cardiovascular Systems Inc (38)